Researchers randomly assigned men 1:1 to ADT and docetaxel plus either 600 mg darolutamide twice daily (n = 651) or placebo (n = 655). OS served as the primary endpoint. Secondary endpoints ...

Back to Healio Docetaxel plus zibotentan failed to significantly improve OS in men with metastatic castration-resistant prostate cancer, according to final phase 3 data from the ENTHUSE clinical ...

Contrast-enhanced chest, abdomen, and pelvic computed tomography or magnetic resonance imaging and bone scans were conducted at baseline, within 30 days of the last docetaxel cycle, and yearly during ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its ...

Risk stratification according to the number of these risk factors could effectively stratify CRPC patients treated with docetaxel in terms of OS. Conclusions: Age, serum PSA level at the start of ...

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

Results showed a statistically significant improvement in OS with darolutamide plus docetaxel compared with placebo plus docetaxel (hazard ratio [HR], 0.68; 95% CI, 0.57-0.80; P <.0001).

In that time, studies of drugs involving Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq and Merck & Co.’s Keytruda have all failed to better the OS achieved by docetaxel. Gilead Sciences ...

One-knot spline models on the hazards scale were fit separately to nivolumab and docetaxel data. Final OS and PFS distributions used in the base-case analyses for nivolumab and docetaxel are shown ...

Astellas and Pfizer have reported five-year follow-up outcomes from the open-label extension of the randomised Phase III ARCHES trial. The study indicated that Xtandi (enzalutamide), combined with ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX ... progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) when compared with FOLFOX ...

The primary endpoint of the trial, extension in overall survival (OS), was achieved. Patients treated with Optune Lua concurrently with an immune checkpoint inhibitor or docetaxel demonstrated a ...